Kevin Schultz, Chief Scientific Officer at Kindred Biosciences, Inc. (KIN), bought 4,000 shares at $7.00 ($28K) on 2013-12-12, disclosed to the SEC on 2013-12-13.
Open-market purchase of $28k KIN by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.